Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model |
Park, Min Hee
(Stem Cell Neuroplasticity Research Group, Kyungpook National University)
Jung, In Kyung (Stem Cell Neuroplasticity Research Group, Kyungpook National University) Min, Woo-Kie (Department of Orthopaedic Surgery, Kyungpook National University Hospital) Choi, Jin Ho (Department of Mechanical Engineering, Gumi University) Kim, Gyu Man (School of Mechanical Engineering, Kyungpook National University) Jin, Hee Kyung (Stem Cell Neuroplasticity Research Group, Kyungpook National University) Bae, Jae-sung (Stem Cell Neuroplasticity Research Group, Kyungpook National University) |
1 | Aloe L, Manni L, Properzi F, De Santis S and Fiore M (2000) Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 86, 84-93 DOI |
2 | Kawamoto T (2003) Use of a new adhesive film for the preparation of multipurpose fresh-frozen sections from hard tissues, whole-animals, insects and plants. Arch Histol Cytol 66, 123-143 DOI |
3 | Blanchard EM (2012) Cisplatin and solid tumours: still working, after all these years. J Solid Tumors 2, 26-33 |
4 | Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 DOI |
5 | Wang D and Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4, 307-320 DOI |
6 | Cepeda V, Fuertes MA, Castilla J, Alonso C, Queve-do C and Perez JM (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7, 3-18 DOI |
7 | Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99, 4592-4595 DOI |
8 | Cullen KJ, Yang Z, Schumaker L and Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39, 43-50 DOI |
9 | Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM and Group GO (2007) A phase I study of paclitaxel, topotecan, cisplatin and filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 105, 667-671 DOI |
10 | Ridwelski K, Gebauer T, Fahlke J et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12, 47-51 |
11 | Niell HB, Herndon JE, Miller AA et al (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23, 3752-3759 DOI |
12 | Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC and Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35, 304-311 DOI |
13 | Zukowska-Grojec Z (1995) Neuropeptide Y. A novel sympathetic stress hormone and more. Ann NY Acad Sci 771, 219-233 DOI |
14 | Pabla N, Dong G, Jiang M et al (2011) Inhibition of reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 121, 2709-2722 DOI |
15 | Hatzopoulos S, Di Stefano M, Albertin A and Martini A (1999) Evaluation of cisplatin ototoxicity in a rat animal model. Ann NY Acad Sci 884, 211-225 DOI |
16 | Noach EJ, Ausema A, van Os R et al (2000) Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice. Exp Hematol 28, 1325-1333 DOI |
17 | Banfi A, Podesta M, Fazzuoli L et al (2001) High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 92, 2419-2428 DOI |
18 | Lucas D, Scheiermann C, Chow A et al (2013) Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med 19, 695-703 DOI |
19 | Kalra SP and Kalra PS (2004) NPY and cohorts in regulation appetite, obesity and metabolic syndrome: beneficial effects of gene therapy. Neuropeptides 38, 201-211 DOI |
20 | Kuo LE, Kitlinska JB, Tilan JU et al (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13, 803-811 DOI |
21 | Santos-Carvalho A, Elvas F, Alvaro AR, Ambrosio AF and Cavadas C (2013) Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis 4, e636 DOI |
22 | Perseghin P, Terruzzi E, Dassi M et al (2009) Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 41, 33-37 DOI |
23 | Park MH, Jin HK, Min WK et al (2015) Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow. EMBO J 34, 1648-1660 DOI |
24 | Park MH, Min WK, Jin HK and Bae JS (2015) Role of neuropeptide Y in the bone marrow hematopoietic stem cell microenvironment. BMB Rep 48, 645-646 DOI |
25 | Can A (2008) Haematopoietic stem cells niches: Interrelations between structure and function. Transfus Apher Sci 38, 261-268 DOI |
26 | Butler JM, Nolan DJ, Vertes EL et al (2010) Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6, 251-264 DOI |
27 | Robinson SN, Freedman AS, Neuberg DS, Nadler LM and Mauch PM (2000) Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34+, CD34+38- and week-6 CAFC assays predict poor engraftment. Exp Hematol 28, 1325-1333 DOI |
28 | Park MH, Lee JK, Kim N et al (2016) Neuropeptide Y Induces Hematopoietic Stem/Progenitor Cell Mobilization by Regulating Matrix Metalloproteinase-9 Activity through Y1 Receptor in Osteoblasts. Stem Cells 34, 2145-2156 DOI |
29 | Kim N, Min WK, Park MH, Lee JK, Jin HK and Bae JS (2016) Neuropeptide Y protects kidney against cisplatininduced nephrotoxicity by regulating p53-dependent apoptosis pathway. BMB Rep 49, 288-292. DOI |